SAN FRANCISCO, June 7, 2019 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic
medicines company focused on developing and commercializing
innovative products for serious rare neuromuscular diseases,
announced it has granted equity awards on June 5, 2019, that
were previously approved by the Compensation Committee of its Board
of Directors under the Audentes Therapeutics, Inc. 2018 Equity
Inducement Plan, as a material inducement to employment to nine
individuals hired by Audentes from April 25
through May 31, 2019. The equity awards were approved
in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase
22,800 shares of Audentes common stock. The options have an
exercise price of $37.31 per share, which is equal to the
closing price of Audentes common stock on June 5, 2019.
One-fourth of the shares underlying each employee's option will
vest on the one year anniversary of his or her date of hire and
thereafter 1/48th of the shares underlying each
employee's option will vest monthly, such that the shares
underlying the option granted to each employee will be fully vested
on the fourth anniversary of his or her date of hire, in each case,
subject to each such employee's continued employment with Audentes
on such vesting dates.
The employees also received, in the aggregate, 14,800 restricted
stock units ("RSUs"). One-fourth of the RSUs will vest on the
first anniversary of the date that vesting of the RSUs commences,
and 1/16th of the RSUs will vest quarterly thereafter,
such that the RSUs will be fully vested on the fourth anniversary
of the date that vesting of the RSUs commences, subject to each
such employee's continued employment with Audentes on such vesting
dates.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a leading AAV-based genetic
medicines company focused on developing and commercializing
innovative products for serious rare neuromuscular diseases.
We are leveraging our AAV gene therapy technology platform and
proprietary manufacturing expertise to develop programs across
three modalities: gene replacement, vectorized exon skipping, and
vectorized RNA knockdown. Our product candidates are showing
promising therapeutic profiles in clinical and preclinical studies
across a range of neuromuscular diseases. Audentes is a
focused, experienced and passionate team driven by the goal of
improving the lives of patients.
For more information regarding Audentes, please visit
www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contacts:
Sarah Spencer
415.957.2020
sspencer@audentestx.com
Katie Hogan
415.951.3398
khogan@audentestx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-300863550.html
SOURCE Audentes Therapeutics, Inc.